Synthesis of novel curcumin analogues for inhibition of 11β-hydroxysteroid dehydrogenase type 1 with anti-diabetic properties

European Journal of Medicinal Chemistry

Volumn 77, Issue , 2014, Pages 223-230

  Yuan, Xiaohuan ^a,b   Li, Hongzhi ^b   Bai, He ^b   Su, Zhijian ^a   Xiang, Qi ^a   Wang, Chaonan ^b   Zhao, Binghai ^b   Zhang, Yufei ^b   Zhang, Qihao ^a   Chu, Yanhui ^b   Huang, Yadong ^a  

^a JINAN UNIVERSITY   (China)

^b MUDANJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Anti diabetic activity; Curcumin analogues; Pharmacokinetic; Stability

Indexed keywords

(1,4) 1,5 BIS (2 BROMO 6 FLUOROPHENYL)PENTA 1,4 DIEN 3 ONE; (1,4) 1,5 BIS (2 BROMOPHENYL)PENTA 1,4 DIEN 3 ONE; (2,5) 2,5 BIS (2 BROMO 6 FLUOROBENZYLIDENE)CYCLOPENTANONE; (2,5) 2,5 BIS (2,6 DIFLUOROBENZYLIDENE)CYCLOPENTANONE; (2,5) 2,5 BIS [2 FLUORO 6 (TRIFLUOROMETHYL)BENZYLIDENE]CYCLOPENTANONE; (2,6) 2,6 BIS (2 BROMO 6 FLUOROBENZYLIDENE)CYCLOHEXANONE; (2,6) 2,6 BIS (2,6 FLUOROBENZYLIDENE)CYCLOHEXANONE; (2,6) 2,6 BIS [2 FLUORO 6 (TRIFLUOROMETHYL)BENZYLIDENE]CYCLOPENTANONE; (3,5) 3,5 BIS (2 BROMO 6 FLUOROBENZYLIDENE)PIPERIDIN 4 ONE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; ANTIDIABETIC AGENT; CURCUMIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; LIPID DIET; METABOLISM; MOUSE MUTANT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; CURCUMIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MOLECULAR STRUCTURE; STREPTOZOCIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896523169     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.03.012     Document Type: Article

References (24)

1. H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and J.S. Flier A transgenic model of visceral obesity and the metabolic syndrome Science 294 2001 2166 2170 (Pubitemid 33150673)
2. C.D. Pereira, I. Azevedo, R. Monteiro, and M.J. Martins 11beta-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus Diabetes, Obesity and Metabolism 14 2012 869 881
3. T.M. Stulnig, and W. Waldhausl 11beta-Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes Diabetologia 47 2004 1 11 (Pubitemid 38141933)
4. P.C. White, T. Mune, F.M. Rogerson, K.M. Kayes, and A.K. Agarwal Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess Steroids 62 1997 83 88 (Pubitemid 27065446)
5. P.C. White, T. Mune, and A.K. Agarwal 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess Endocrine Reviews 18 1997 135 156 (Pubitemid 27076458)
6. M.A. Bailey, E. Craigie, D.E. Livingstone, Y.V. Kotelevtsev, E.A. Al-Dujaili, C.J. Kenyon, and J.J. Mullins Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure Hypertension 57 2011 515 520
7. T. Barf, J. Vallgarda, R. Emond, C. Haggstrom, G. Kurz, A. Nygren, V. Larwood, E. Mosialou, K. Axelsson, R. Olsson, L. Engblom, N. Edling, Y. Ronquist-Nii, B. Ohman, P. Alberts, and L. Abrahmsen Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 Journal of Medicinal Chemistry 45 2002 3813 3815 (Pubitemid 35024284)
8. S.C. Gupta, G. Kismali, and B.B. Aggarwal Curcumin, a component of turmeric: from farm to pharmacy Biofactors 39 2013 2 13
9. M.R. Maradana, R. Thomas, and B.J. O'Sullivan Targeted delivery of curcumin for treating type 2 diabetes Molecular Nutrition & Food Research 57 2013 1550 1556
10. B.B. Aggarwal Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals Annual Review of Nutrition 30 2010 173 199
11. G.X. Hu, H. Lin, Q.Q. Lian, S.H. Zhou, J. Guo, H.Y. Zhou, Y. Chu, and R.S. Ge Curcumin as a potent and selective inhibitor of 11beta-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats PLoS One 8 2013 e49976
12. R.A. Sharma, W.P. Steward, and A.J. Gescher Pharmacokinetics and pharmacodynamics of curcumin Advances in Experimental Medicine and Biology 595 2007 453 470
13. G. Garcea, D.J. Jones, R. Singh, A.R. Dennison, P.B. Farmer, R.A. Sharma, W.P. Steward, A.J. Gescher, and D.P. Berry Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration British Journal of Cancer 90 2004 1011 1015 (Pubitemid 38499692)
14. G. Liang, X. Li, L. Chen, S. Yang, X. Wu, E. Studer, E. Gurley, P.B. Hylemon, F. Ye, Y. Li, and H. Zhou Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin Bioorganic & Medicinal Chemistry Letters 18 2008 1525 1529 (Pubitemid 351226515)
15. H. Lin, G.X. Hu, J. Guo, Y. Ge, G. Liang, Q.Q. Lian, Y. Chu, X. Yuan, P. Huang, and R.S. Ge Mono-carbonyl curcumin analogues as 11beta-hydroxysteroid dehydrogenase 1 inhibitors Bioorganic & Medicinal Chemistry Letters 23 2013 4362 4366
16. S.J. Wang, S. Birtles, J. de Schoolmeester, J. Swales, G. Moody, D. Hislop, J. O'Dowd, D.M. Smith, A.V. Turnbull, and J.R. Arch Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice Diabetologia 49 2006 1333 1337
17. Y.J. Wang, M.H. Pan, A.L. Cheng, L.I. Lin, Y.S. Ho, C.Y. Hsieh, and J.K. Lin Stability of curcumin in buffer solutions and characterization of its degradation products Journal of Pharmaceutical and Biomedical Analysis 15 1997 1867 1876
18. M.A. Tomren, M. Masson, T. Loftsson, and H.H. Tonnesen Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin International Journal of Pharmaceutics 338 2007 27 34 (Pubitemid 46777212)
19. G. Liang, L. Shao, Y. Wang, C. Zhao, Y. Chu, J. Xiao, Y. Zhao, X. Li, and S. Yang Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents Bioorganic & Medicinal Chemistry 17 2009 2623 2631
20. J. Guo, X. Yuan, L. Qiu, W. Zhu, C. Wang, G. Hu, Y. Chu, L. Ye, Y. Xu, and R.S. Ge Inhibition of human and rat 11beta-hydroxysteroid dehydrogenases activities by bisphenol A Toxicology Letters 215 2012 126 130
21. Y. Zhang, M. Huo, J. Zhou, and S. Xie PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Computer Methods and Programs in Biomedicine 99 2010 306 314
22. R.S. Ge, and M.P. Hardy Initial predominance of the oxidative activity of type I 11beta-hydroxysteroid dehydrogenase in primary rat Leydig cells and transfected cell lines Journal of Andrology 21 2000 303 310 (Pubitemid 30123712)
23. R.S. Ge, H.B. Gao, V.L. Nacharaju, G.L. Gunsalus, and M.P. Hardy Identification of a kinetically distinct activity of 11beta-hydroxysteroid dehydrogenase in rat Leydig cells Endocrinology 138 1997 2435 2442 (Pubitemid 27215247)
24. P. Klusonova, M. Kucka, I. Miksik, J. Bryndova, and J. Pacha Chicken 11beta-hydroxysteroid dehydrogenase type 2: partial cloning and tissue distribution Steroids 73 2008 348 355